One can't judge a stent by its cover.

摘要

The "law of unintended consequences" states that any purposeful action will produce some unintended consequences.1 The recent acquisition of the Guidant Corporation by Boston Scientific (BS) Corporation, Natick, Massachusetts, has led to policies that (1) promote wasteful spending and delay acquisition of necessary clinical information and (2) expose the inter-ventional cardiology community to a potential appearance of conflict of interest at a time when physician-industry relationships are being carefully scrutinized.2"4 In 2006, BS Corporation purchased Guidant Corporation for Dollars 27 billion. In an attempt to avoid competitive market imbalance, the Federal Trade Commission (FTC) also approved the acquisition of Guidant's vascular business by Abbott Laboratories, Abbott Park, Illinois.